Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TTP607

Small molecule · Inhibitor of Aurora kinase A (AURKA), Aurora kinase B (AURKB) and Aurora kinase C (AURKC)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is TTP607?

TTP607 is a small-molecule pan-Aurora kinase inhibitor that binds and inhibits Aurora kinases A, B and C, serine/threonine kinases essential for mitotic checkpoint control. It is being studied in advanced cancers and lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Aurora kinase A (AURKA), Aurora kinase B (AURKB), Aurora kinase C (AURKC)
Mechanism
Inhibitor of Aurora kinase A (AURKA), Aurora kinase B (AURKB) and Aurora kinase C (AURKC)
Pathways
mitotic spindle assembly, chromosome segregation, cell division
Therapy area
Oncology
In trials of
VTVT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00939172 Phase 1 Advanced Cancers Withdrawn VTVT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancersLymphoma

Other drugs acting on AURKA / AURKB / AURKC

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.